Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas W Geisbert

Showing results (231-240 of 279) with videos related to

Pageof 28
Sort By:
Science Advances|March 14, 2025
The oral drug obeldesivir protects nonhuman primates against lethal Ebola virus infectionCourtney Woolsey, Robert W Cross, Victor C Chu, et al.
Journal of Virology|February 4, 2021
Prominent Neutralizing Antibody Response Targeting the <i>Ebolavirus</i> Glycoprotein Subunit Interface Elicited by ImmunizationYimeng Wang, Katie A Howell, Jennifer Brannan, et al.
Antiviral Research|December 3, 2016
Assessment of the potential for host-targeted iminosugars UV-4 and UV-5 activity against filovirus infections in vitro and in vivoKelly L Warfield, Travis K Warren, Xiangguo Qiu, et al.
Pathogens (Basel, Switzerland)|June 24, 2022
Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a Pan-Ebolavirus ImmunotherapeuticErin Kuang, Robert W Cross, Maria McCavitt-Malvido, et al.
Emerging Microbes & Infections|August 6, 2025
Experimental challenge of African green monkeys with contemporary Hendra virus isolates produces divergent clinical diseaseDeclan D Pigeaud, Karla A Fenton, Jacquelyn Turcinovic, et al.
Biorxiv : the Preprint Server for Biology|June 22, 2026
Finding the Goldilocks zone: Modulating glycoprotein cleavage and fusogenicity optimizes the efficacy of a candidate Crimean-Congo hemorrhagic fever virus vaccineJacob Berrigan, Stephanie R Monticelli, Pieter Spealman, et al.
Cell Reports|September 1, 2021
Cooperativity mediated by rationally selected combinations of human monoclonal antibodies targeting the henipavirus receptor binding proteinMichael P Doyle, Nurgun Kose, Viktoriya Borisevich, et al.
Science Translational Medicine|December 14, 2022
A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primatesRuth Hunegnaw, Anna N Honko, Lingshu Wang, et al.
Plos One|February 21, 2018
A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primatesBenoit Callendret, Jort Vellinga, Kerstin Wunderlich, et al.
Plos One|April 25, 2018
Correction: A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primatesBenoit Callendret, Jort Vellinga, Kerstin Wunderlich, et al.
Pageof 28

Showing results (231-240 of 279) with videos related to

Sort By:
Pageof 28
Science Advances|March 14, 2025
The oral drug obeldesivir protects nonhuman primates against lethal Ebola virus infectionCourtney Woolsey, Robert W Cross, Victor C Chu, et al.
Journal of Virology|February 4, 2021
Prominent Neutralizing Antibody Response Targeting the <i>Ebolavirus</i> Glycoprotein Subunit Interface Elicited by ImmunizationYimeng Wang, Katie A Howell, Jennifer Brannan, et al.
Antiviral Research|December 3, 2016
Assessment of the potential for host-targeted iminosugars UV-4 and UV-5 activity against filovirus infections in vitro and in vivoKelly L Warfield, Travis K Warren, Xiangguo Qiu, et al.
Pathogens (Basel, Switzerland)|June 24, 2022
Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a Pan-Ebolavirus ImmunotherapeuticErin Kuang, Robert W Cross, Maria McCavitt-Malvido, et al.
Emerging Microbes & Infections|August 6, 2025
Experimental challenge of African green monkeys with contemporary Hendra virus isolates produces divergent clinical diseaseDeclan D Pigeaud, Karla A Fenton, Jacquelyn Turcinovic, et al.
Biorxiv : the Preprint Server for Biology|June 22, 2026
Finding the Goldilocks zone: Modulating glycoprotein cleavage and fusogenicity optimizes the efficacy of a candidate Crimean-Congo hemorrhagic fever virus vaccineJacob Berrigan, Stephanie R Monticelli, Pieter Spealman, et al.
Cell Reports|September 1, 2021
Cooperativity mediated by rationally selected combinations of human monoclonal antibodies targeting the henipavirus receptor binding proteinMichael P Doyle, Nurgun Kose, Viktoriya Borisevich, et al.
Science Translational Medicine|December 14, 2022
A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primatesRuth Hunegnaw, Anna N Honko, Lingshu Wang, et al.
Plos One|February 21, 2018
A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primatesBenoit Callendret, Jort Vellinga, Kerstin Wunderlich, et al.
Plos One|April 25, 2018
Correction: A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primatesBenoit Callendret, Jort Vellinga, Kerstin Wunderlich, et al.
Pageof 28